Gilead Sciences, Inc. (GILD) EPS Estimated At $1.67

January 19, 2018 - By simple simple

 Gilead Sciences, Inc. (GILD) EPS Estimated At $1.67
Investors sentiment increased to 1.03 in Q3 2017. Its up 0.10, from 0.93 in 2017Q2. It increased, as 96 investors sold Gilead Sciences, Inc. shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported.
Royal National Bank Of Scotland Group Incorporated Public Limited Com holds 5.29% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 263,309 shares. Grassi Invest reported 5,200 shares. Fairfield Bush Co stated it has 5,715 shares. Mutual Of America Cap Management Lc invested 0.28% in Gilead Sciences, Inc. (NASDAQ:GILD). Moreover, Charter Trust has 0.1% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 10,374 shares. Royal Financial Bank Of Canada, a Ontario – Canada-based fund reported 3.24 million shares. Fiduciary holds 0.29% or 117,811 shares in its portfolio. Pnc Financial Serv Incorporated holds 0.05% or 650,866 shares in its portfolio. Utah Retirement holds 0.43% in Gilead Sciences, Inc. (NASDAQ:GILD) or 238,686 shares. New York-based Lipe & Dalton has invested 2.88% in Gilead Sciences, Inc. (NASDAQ:GILD). 9,717 were accumulated by Kcm Inv Limited Liability Company. Mackenzie Fincl Corp reported 444,737 shares stake. Endurance Wealth holds 0.35% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 26,160 shares. Reliance Company Of Delaware reported 6,208 shares. Webster Comml Bank N A invested in 0.02% or 1,403 shares.

Since August 1, 2017, it had 0 insider buys, and 12 insider sales for $43.50 million activity. Alton Gregg H sold $2.08M worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Friday, September 1. 73,333 shares valued at $5.56M were sold by MARTIN JOHN C on Tuesday, August 1. Washington Robin L sold $4.40M worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, September 7.

Analysts expect Gilead Sciences, Inc. (NASDAQ:GILD) to report $1.67 EPS on February, 6.They anticipate $0.97 EPS change or 36.74 % from last quarter’s $2.64 EPS. GILD’s profit would be $2.18 billion giving it 12.12 P/E if the $1.67 EPS is correct. After having $2.23 EPS previously, Gilead Sciences, Inc.’s analysts see -25.11 % EPS growth. The stock decreased 0.25% or $0.2 during the last trading session, reaching $80.97. About 4.29 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since January 19, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences had 112 analyst reports since July 29, 2015 according to SRatingsIntel. As per Monday, January 18, the company rating was upgraded by Bank of America. The stock has “Hold” rating by BMO Capital Markets on Tuesday, January 2. The rating was maintained by Oppenheimer with “Outperform” on Wednesday, July 29. The rating was upgraded by Bank of America to “Neutral” on Friday, January 15. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Hold” rating given on Tuesday, October 3 by Needham. The stock has “Buy” rating by Jefferies on Tuesday, September 6. The rating was maintained by Oppenheimer on Thursday, December 21 with “Hold”. Cowen & Co maintained the shares of GILD in report on Tuesday, May 30 with “Buy” rating. Atlantic Securities initiated Gilead Sciences, Inc. (NASDAQ:GILD) rating on Friday, December 18. Atlantic Securities has “Neutral” rating and $111 target. The firm has “Hold” rating by Jefferies given on Tuesday, July 11.

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company has market cap of $105.77 billion. The company??s products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It has a 9.22 P/E ratio. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “2018 Is Gilead’s Year” on January 16, 2018, also Seekingalpha.com with their article: “Gilead: Buy Or Wait?” published on January 08, 2018, Seekingalpha.com published: “Gilead’s 2018 And Beyond – Buckle Up For A New Gilead” on December 22, 2017. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Omaha.com and their article: “On Investments: CVS, Gilead Sciences hit the Casualty List” published on January 16, 2018 as well as Forbes.com‘s news article titled: “The Intrinsic Value Of Gilead Science” with publication date: January 01, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.